Canton Strategic (CNTN) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Canton Strategic (CNTN) has outperformed Humacyte (HUMA) over the past year, losing 34.6% versus a loss of 73.5%. Canton Strategic is the larger company by market cap ($165.7 million vs $124.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | HUMA |
|---|---|---|
| Share price | $2.08 | $0.4471 |
| Market cap | $165.74M | $124.20M |
| 1-day change | -7.96% | -5.34% |
| YTD return | -31.35% | -53.48% |
| 1-year return | -34.59% | -73.54% |
| 5-year return | — | -95.63% |
| EPS (TTM) | $-0.09 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $1.90 |
| 52-week low | $1.75 | $0.4367 |
| Distance from 52-week high | -69.81% | -76.41% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +264.57% |
| Average volume | 758.86K | 6.30M |
| Shares outstanding | 79.68M | 277.80M |
| Employees | 12 | 184 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed HUMA by 39.0 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
CNTN vs HUMA FAQ
Which is bigger, Canton Strategic or Humacyte?
Canton Strategic (CNTN) is larger, with a market capitalization of $165.74M compared with $124.20M for Humacyte (HUMA).
Which stock has performed better over the past year, CNTN or HUMA?
CNTN returned -34.59% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.